Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
The accelerated approval pathway facilitates earlier approval of drugs that treat serious conditions.
Cabometyx is the third liver cancer drug approved in the past six months.
Four out of 10 FDA workers are sidelined.
Asparlas approved for children and young adults with acute lymphoblastic leukemia.
Elzonris approved for bone marrow disease that can evolve into leukemia.
Pembrolizumab led to 56 percent overall response rate for rare skin cancer.
PARP inhibitor slowed disease progression in clinical study.
Checkpoint inhibitor immunotherapy, alone or in combination with chemotherapy, shows promise for advanced non-small-cell lung cancer.
Roger Pebody is a medical journalist and the managing editor of aidsmap.com. He lives in London with his husband, Jean-Michel.
The FDA recently approved Vitrakvi for all cancers with specific gene mutation.
Human papillomavirus vaccine can prevent cervical, anal and oral cancers.
Talazoparib slowed disease progression compared to chemotherapy in EMBRACA study.
Tecentriq plus chemotherapy and Avastin delays disease progression and death.
A clinical trial showed that 21 percent of participants achieved complete remission.
Review of evidence indicates Truxima works similarly to Rituxan.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.